Targeted protein degradation (TPD) is an emerging therapeutic modality with the potential to
tackle disease-causing proteins that have historically been highly challenging to target with …

Traditional drug discovery mainly focuses on direct regulation of protein activity. The
development and application of protein activity modulators, particularly inhibitors, has been …

Natural killer (NK) cells have crucial roles in the innate immunosurveillance of cancer and
viral infections. They are 'first responders' that can spontaneously recognize abnormal cells …

Analyses of publicly available structural data reveal interesting insights into the impact of the
three‐dimensional (3D) structures of protein targets important for discovery of new drugs …

Objective Evaluating the efficacy of 3, 6'‐dithioPomalidomide in 5xFAD Alzheimer's disease
(AD) mice to test the hypothesis that neuroinflammation is directly involved in the …

The ubiquitin-proteasome pathway (UPP) is involved in regulating several biological
functions, including cell cycle control, apoptosis, DNA damage response, and apoptosis. It is …

Triple-negative breast cancers (TNBC) frequently inactivate p53, increasing their
aggressiveness and therapy resistance. We identified an unexpected protein vulnerability in …

Thalidomide, originally developed as a sedative drug, causes multiple defects due to severe
teratogenicity, but it has been re-purposed for treating multiple myeloma, and derivatives …

Immunomodulatory agents (IMiDs) are a cornerstone of treatment for patients with multiple
myeloma. IMiDs are used in therapeutic combinations at all stages of disease and are …

Epigenetic enzymes histone deacetylases (HDACs) are clinically validated anticancer drug
targets which have been studied intensively in the past few decades. Although several drugs …